Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.2.1-2 | Award Amount: 8.13M | Year: 2013
Mental disorders are leading causes of disability, absence from work and premature retirement in Europe. While magnetic resonance imaging (MRI) facilities are broadly available and a vast research literature exists, few neuroimaging applications have reached clinical practice in psychiatry. A major problem is that mental illnesses are currently diagnosed as discrete entities defined clinically. Instead, recent results show that mental disorders are best understood as quantitative alterations in neural systems relevant across traditional diagnostic boundaries that reflect individual, genetic and environmental risk factors. In the IMAGEMEND consortium, we aim to discover these systems to identify the patient characteristics most relevant for treatment, derive biomarkers and decision rules from this systems-level dimensional account, and systematically validate biomarker panels in patient, high-risk and epidemiological samples to produce automated imaging-based diagnostic and predictive tests tailored for wide distribution throughout Europe in standard clinical settings. Focusing on schizophrenia, bipolar disorder and attention deficit-hyperactivity disorder, we have assembled Europes largest dataset combining neuroimaging, genetic, environmental, cognitive and clinical information on approximately 13000 participants, and have recruited international replication datasets of more than 30000 people. This unique resource will be processed using a new generation of multivariate statistical analysis to optimize existing imaging technology for the benefit of patients. We will also develop new imaging technology to enable the direct imaging-based therapeutic modification of neural circuits through rapid real-time MRI. Our deliverables will promote personalized treatment through more accurate patient stratification, allow diagnoses at the pre-symptomatic stage for early intervention and prevention, and improve prediction of treatment response and disease progression.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2013.2.2.1-4 | Award Amount: 15.74M | Year: 2013
Epilepsy is a devastating condition affecting over 50 million people worldwide. This multidisciplinary project is focused on the process leading to epilepsy, epileptogenesis, in adults. Our main hypothesis is that there are combinations of various causes, acting in parallel and/or in succession, that lead to epileptogenesis and development of seizures. Our central premise and vision is that a combinatorial approach is necessary to identify appropriate biomarkers and develop effective antiepileptogenic therapeutics. The project will focus on identifying novel biomarkers and their combinations for epileptogenesis after potentially epileptogenic brain insults in clinically relevant animal models, such as traumatic brain injury (TBI) and status epilepticus (SE); explore multiple basic mechanisms of epileptogenesis and their mutual interactions related to cell degeneration, circuit reorganization, inflammatory processes, free radical formation, altered neurogenesis, BBB dysfunction, genetic and epigenetic alterations; and translating these findings towards the clinic by validating biomarkers identified from animal models in human post TBI brain tissue and blood samples, post-mortem brain tissue in individuals that died soon after SE, and human brain and blood samples from chronic epilepsy cases. The project will identify novel combinatorial biomarkers and novel disease-modifying combinatorial treatment strategies for epileptogenesis, create an Epilepsy Preclinical Biobank, and validate translational potential of results from animal models in human tissue. To adequately address the proposed goals, the project will develop technological breakthroughs, such as completely novel chemogenetic approaches, novel MRI techniques, novel multimodal organic recording devices for simultaneous recordings of EEG / cellular unit activity and biochemical measurements, novel bioluminescence for in vivo promoter activity analysis, and novel systems biology approaches.
Agency: European Commission | Branch: FP7 | Program: CSA-CA | Phase: HEALTH-2009-4.1-2 | Award Amount: 848.43K | Year: 2010
The European Consortium for Communicating Stem Cell Research, EUROSTEMCELL, brings together the major current FP6 and FP7 stem cell projects, the European Clinical Research Infrastructure Network, and four internationally recognized European stem cell centres to develop a comprehensive, coordinated platform for collation, dissemination and archiving of information on stem cell biology and regenerative medicine. Our aims are to address the urgent need for trusted, high quality information on stem cells by citizens and stakeholders across Europe, and further to establish a model for large-scale dissemination of Framework-funded research outputs to European publics. Dissemination of key advances will be achieved through a structured approach aimed at reaching European citizens and stakeholders at all educational levels. We will focus on three major dissemination routes: the worldwide web; resources for direct public engagement; and resources for educators. Emphasis will be placed on clear exposition of the potential applications and benefits for citizens of existing knowledge and new developments in stem cell research. To ensure continuous development of best practice, we will iteratively evaluate and refine all activities throughout the project. The project centrepiece will be a multi-lingual website, the European Stem Cell Information Portal www.eurostemcell.org, which we will create and develop as the premier European reference site for stem cell information and discourse. The consortium comprises the principal stem cell laboratories across Europe, including new member states, and additionally offers outstanding expertise in ethical and societal concerns and in evaluating clinical outcomes. This coalition provides unparalleled expertise across the field of stem cell biology and regenerative medicine, and is uniquely placed to achieve the vision of a trusted and accessible European stem cell information resource that promotes and facilitates public dialogue.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: Health | Award Amount: 2.25M | Year: 2015
The European Consortium for Communicating Stem Cell Research (EuroStemCell) unites 33 partner institutions, that collectively represent >400 stem cell research groupings across Europe. Our common goal is to provide trusted high quality information on stem cells accessible to citizens and stakeholders across Europe, through support and further development of the multi-lingual European Stem Cell Information Portal www.eurostemcell.org. To achieve our aims, EuroStemCell will adopt the highly structured system for coordinated information management established by the FP7 Coordination and Support Action (CSA) also called EuroStemCell. From this, we will implement an ambitious programme of online and direct stakeholder engagement with stem cell research and regenerative medicine, aimed at European citizens at all educational levels. This will include provision of resources tailored specifically for decision-making on stem cell-related questions and an extensive programme of dissemination and capacity building in science communications and public engagement. The proposed work centres on an information hub team, which will link to all project partners and to stakeholders in the stem cell and regenerative medicine arenas and wider society, working with these groupings to implement the project. All outputs will be delivered in 6 European languages, to ensure broad accessibility, and will be rigorously evaluated against measurable objectives throughout the project duration. The proposed consortium comprises leading stem cell labs across Europe, including new member states, together with experts in ethical and societal concerns and evaluating clinical outcomes. It thus provides unparalleled European expertise across the fields of stem cell biology and regenerative medicine and is uniquely placed to maintain and further develop www.eurostemcell.org as a world-leading stem cell information resource, thus meeting the challenge outlined in Topic HOA-6-2014.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-03-2015 | Award Amount: 6.00M | Year: 2016
COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism, and schizophrenia. We capitalise on comorbidity, from clinic to cells and synapses, and have access to large existing samples. We focus on rare genetic variants of strong effect in patients with clinical comorbidity. Our aims are: (1) Understand comorbidity by comparing symptom and syndrome overlap with novel neurobiological criteria; (2) Elucidate mechanisms of comorbidity using neurobiology for the major genomic clue of synaptic dysfunction to unravel the cellular mechanisms of comorbidity; (3) Generate novel neuronal cell models by using advanced technologies to make neurons from carefully selected patients, and use genome editing to create or correct genetic variants. Multiple advanced neuroscience platforms are in place to evaluate an extensive set of molecular and cellular parameters, and to identify alterations in synaptic biology characteristic of ID, autism, and schizophrenia. These cellular models will, with Pharma partners, be up-scaled to provide industry-standard cellular assays for compound screening; (4) Refine diagnostic tools, use novel genomic and cellular features to improve disease classification and discriminate specific patient subtypes; and (5) Case studies in precision medicine: with Pharma partners, identify patients with a genetic change whose consequences can be reproducibly ameliorated in vitro by an approved medication. Recommend to the patient and clinician a double-blinded, N-of-one crossover case study to evaluate the clinical utility of a medication precisely indicated for that person. COSYN is an integrated, state-of-art, bench-to-bedside programme focused on personalised therapeutics. COSYN is a crucial next step in decoding the genetic findings via intensive focus on the clinical and molecular comorbidities of ID, autism, and schizophrenia.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.1.4-1 | Award Amount: 7.97M | Year: 2013
Neurostemcellrepair aims at taking human stem cells through the final steps toward clinical application in cell replacement therapy for neurological disorders. PD will be taken as the prototypical disease because stem cell therapy is now close to clinical translation. Moreover, we will tackle next generation issues pertaining to stem cells at a basic level and develop new approaches and novel cell sources, validated at pre-clinical stages, for both PD and HD. The project teams represent a wide range of competences, including stem cell specialists, developmental neurobiologists, experts in neurodegeneration, scientists with links to the clinic and stem cell manufacturing/clinical validation. The research plan is constructed on exchange of tools, sharing of protocols and expertise and joint deliverables among the participants. We will address issues related to the control of progenitor proliferation and differentiation into authentic, functional and phenotypically stable dopaminergic or striatal neurons, and exploit new technology for cell reprogramming. We will develop strategies to obtain endurable donor cell engraftment in the host, including acquisition of specific neuronal identities and functional integration in the recipient brain. The therapeutic effect will be evaluated following transplantation in animal models of PD and HD. Cutting edge technologies will be guaranteed by the involvement of three SMEs, one industry and partners experienced in bioengineering, who will collectively provide a toolbox to deliver ontogenetic and reprogramming factors, small molecules and miRNA, immunoseparation strategies, in vivo monitoring of donor cell behaviour, scale up and GMP-compliant protocols. Ultimately, Neurostemcellrepair is expected to develop new cell sources based on cellular reprogramming, make significant advance towards stem cell therapy in HD, and close the gap between development and clinical implementation of stem cell replacement therapies for PD.
Life and Brain GmbH | Date: 2012-06-15
The present invention relates to glioblastoma inhibiting compounds, in particular gambogic acid amid and derivatives thereof for the treatment of glioblastoma. Moreover, methods for determining whether a treatment with the compounds of the invention is suitable for a patient are disclosed.
Life and Brain GmbH | Date: 2013-08-06
The present invention relates to novel therapeutic uses of niclosamide for the treatment of cancer. In particular, a combination of niclosamide or one of its derivatives with an alkylating agent is provided for the treatment of solid tumors. Moreover, niclosamide or one of its derivatives can be used for the treatment of solid tumors characterized by underexpression of NFKBIA. Finally, the invention relates to diagnostic methods for determining whether treatment with niclosamide alone or in combination with an alkylating agent is suitable for a cancer patient.
Life and Brain GmbH | Date: 2012-06-20
Life and Brain GmbH | Date: 2013-07-08
The invention relates to a fusion protein and a method for the generation of the fusion protein of the invention. Further, the invention relates to the use of the fusion protein of the invention for the generation of induced pluripotent cells. Moreover, the invention relates to a composition comprising at least one fusion protein of the invention.